Inventor · disambiguated record
Jason Katz
Also filed as: KATZ JASON · KATZ JASON D · KATZ JASON DAVID
26 granted patents·35 pending applications·60 citations·filing 2006–2024
93Inventor score
Top patents by PatentIndex Score
61 records- 0190US11724992B2Compounds and compositions for treating conditions associated with NLRP activityNOVARTIS AG·Filed 2021·Granted Aug 15, 2023·1 cites·20 claims
- 0290US8455477B2Therapeutic compoundsKATZ JASON·Filed 2009·Granted Jun 4, 2013·34 cites·7 claims
- 0384US12084424B2Compounds and compositions for treating conditions associated with NLRP activityNOVARTIS AG·Filed 2023·Granted Sep 10, 2024·0 cites·3 claims
- 0484US11370763B2Compounds and compositions for treating conditions associated with NLRP activityNOVARTIS AG·Filed 2018·Granted Jun 28, 2022·1 cites·13 claims
- 0584US10654816B2Compounds and compositions for treating conditions associated with NLRP activityNOVARTIS INFLAMMASOME RES INC·Filed 2019·Granted May 19, 2020·3 cites·19 claims
- 0683US12152018B2Compounds and compositions for treating conditions associated with STING activityIFM DUE INC·Filed 2022·Granted Nov 26, 2024·1 cites·36 claims
- 0783US7550478B2Tyrosine kinase inhibitorsMERCK & CO INC·Filed 2006·Granted Jun 23, 2009·7 cites·9 claims
- 0881US11203579B2Compounds and compositions for treating conditions associated with NLRP activityNOVARTIS AG·Filed 2018·Granted Dec 21, 2021·2 cites·19 claims
- 0977US2024391884A1Compounds and compositions for treating conditions associated with nlrp activityNOVARTIS AG·Filed 2024·Application pending·0 cites
- 1074US8207186B2Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase METJEWELL JAMES P·Filed 2006·Granted Jun 26, 2012·3 cites·1 claims
- 1173US9730940B2Purine inhibitors of human phosphatidylinositol 3-kinase deltaMERCK SHARP & DOHME·Filed 2013·Granted Aug 15, 2017·3 cites·9 claims
- 1271US9725445B2Cycloalkyl nitrile pyrazolo pyridones as Janus kinase inhibitorsMERCK SHARP & DOHME·Filed 2014·Granted Aug 8, 2017·2 cites·17 claims
- 1370US2025136597A1Compounds and compositions for treating conditions associated with sting activityIFM DUE INC·Filed 2024·Application pending·0 cites
- 1466US9957264B2Geminally substituted cyanoethylpyrazolo pyridones as Janus kinase inhibitorsMERCK SHARP & DOHME·Filed 2014·Granted May 1, 2018·1 cites·9 claims
- 1565US12421223B2Compounds and compositions for treating conditions associated with NLRP activityNOVARTIS AG·Filed 2019·Granted Sep 23, 2025·0 cites·1 claims
- 1665US8518911B2Pyrazolo[1,5-a]pyridines as MARK inhibitorsKATZ JASON D·Filed 2009·Granted Aug 27, 2013·1 cites·19 claims
- 1763US10100064B2Purine inhibitors of human phosphatidylinositol 3-kinase deltaMERCK SHARP & DOHME·Filed 2015·Granted Oct 16, 2018·1 cites·11 claims
- 1862US2025084071A1Compounds and compositions for treating conditions associated with sting activityNOVARTIS PHARMA AG·Filed 2023·Application pending·0 cites
- 1960US12503436B2Compounds and compositions for treating conditions associated with STING activityNOVARTIS PHARMA AG·Filed 2022·Granted Dec 23, 2025·0 cites·86 claims
- 2060US2023079631A1Compounds and compositions for treating conditions associated with nlrp activityNOVARTIS AG·Filed 2022·Application pending·0 cites
- 2159US2022024919A1Compounds and compositions for treating conditions associated with sting activityIFM DUE INC·Filed 2021·Application pending·0 cites
- 2258US2023250060A1Compounds and compositions for treating conditions associated with sting activityIFM DUE INC·Filed 2023·Application pending·0 cites
- 2356US2024076285A1Compounds and compositions for treating conditions associated with sting activityVENKATRAMAN SHANKAR·Filed 2021·Application pending·0 cites
- 2455US9328099B2Cyanomethylpyrazole carboxamides as janus kinase inhibitorsBRUBAKER JASON·Filed 2012·Granted May 3, 2016·0 cites·19 claims
- 2554US2024101556A1Compounds and compositions for treating conditions associated with sting activityIFM DUE INC·Filed 2022·Application pending·0 cites
- 2654US2024083879A1Oxalamide compounds and compositions for treating conditions associated with sting activityIFM DUE INC·Filed 2022·Application pending·0 cites
- 2754US2024308978A1Compounds and compositions for treating conditions associated with sting activityIFM DUE INC·Filed 2022·Application pending·0 cites
- 2854US2022387397A1Compounds and compositions for treating conditions associated with nlrp activityNOVARTIS AG·Filed 2019·Application pending·0 cites
- 2953US2024051970A1Compounds and compositions for treating conditions associated with sting activityIFM DUE INC·Filed 2021·Application pending·0 cites
- 3053US2021395241A1Nlrp modulatorsNOVARTIS AG·Filed 2019·Application pending·0 cites
- 3152US2023271941A1Compounds and compositions for treating conditions associated with sting activityIFM DUE INC·Filed 2021·Application pending·0 cites
- 3252US2023250106A1Compounds and compositions for treating conditions associated with sting activityIFM DUE INC·Filed 2021·Application pending·0 cites
- 3352US2022227707A1Compounds and compositions for treating conditions associated with nlrp activityNOVARTIS AG·Filed 2020·Application pending·0 cites
- 3452US2022024906A1Compounds and compositions for treating conditions associated with sting activityIFM DUE INC·Filed 2021·Application pending·0 cites
- 3552US2023250088A1Compounds and compositions for treating conditions associated with sting activityIFM DUE INC·Filed 2021·Application pending·0 cites
- 3652US2023365553A1Compounds and compositions for treating conditions associated with sting activityIFM DUE INC·Filed 2021·Application pending·0 cites
- 3751US11179389B2Purine inhibitors of human phosphatidylinositol 3-kinase deltaMERCK SHARP & DOHME·Filed 2018·Granted Nov 23, 2021·0 cites·13 claims
- 3850US2023063462A1Sulfonimidamide compounds and compositions for treating conditions associated with nlrp activityNOVARTIS AG·Filed 2020·Application pending·0 cites
- 3949US2023115274A1Compounds and compositions for treating conditions associated with sting activityIFM DUE INC·Filed 2020·Application pending·0 cites
- 4049US2023127839A1Compounds and compositions for treating conditions associated with sting activityIFM DUE INC·Filed 2020·Application pending·0 cites
- 4149US2022339169A1Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a nlrp3 antagonistNOVARTIS AG·Filed 2019·Application pending·0 cites
- 4248US12134611B2Compounds and compositions for treating conditions associated with NLRP activityNOVARTIS AG·Filed 2019·Granted Nov 5, 2024·0 cites·20 claims
- 4348US2023002320A1Compounds and compositions for treating conditions associated with sting activityIFM DUE INC·Filed 2020·Application pending·0 cites
- 4448US2023021448A1Compounds and compositions for treating conditions associated with sting activityIFM DUE INC·Filed 2020·Application pending·0 cites
- 4548US2022227760A1Compounds and compositions for treating conditions associated with sting activityIFM DUE INC·Filed 2020·Application pending·0 cites
- 4648US2023059136A1The compounds and compositions for treating conditions associated with nlrp activityNOVARTIS AG·Filed 2019·Application pending·0 cites
- 4748US2023092163A1Compounds and compositions for treating conditions associated with sting activityIFM DUE INC·Filed 2020·Application pending·0 cites
- 4848US2023031406A1Compounds and compositions for treating conditions associated with nlrp activityNOVARTIS AG·Filed 2019·Application pending·0 cites
- 4948US2023051589A1Compounds and compositions for treating conditions associated with nlrp activityNOVARTIS AG·Filed 2019·Application pending·0 cites
- 5047US2023002373A1Compounds and compositions for treating conditions associated with sting activityIFM DUE INC·Filed 2020·Application pending·0 cites
Showing the top 50 of 61 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →